Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER22-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined